Results 171 to 180 of about 645,855 (340)
Clinical Pharmacology &Therapeutics, EarlyView.Novel compounds targeting the adaptive immune system are commonly initially investigated in healthy volunteers (HV). HV frequently lack constitutively expressed drug‐target engagement biomarkers, complicating the evaluation of pharmacological activity. The keyhole limpet hemocyanin (KLH) neo‐antigen challenge elicits a controlled immune response in HV ...
Micha N. Ronner +10 more
wiley +1 more source
Present Position of Immunization Against Poliomyelitis with Live Virus Vaccines [PDF]
, 1959 A. B. Sabin
openalex +1 more source
Ontogeny of RSPO1, FOXL2, and RUNX1 during ovarian differentiation in the marsupial tammar wallaby
Developmental Dynamics, EarlyView.Abstract Background RSPO1 and FOXL2 are female sex‐determining genes involved in the differentiation and organization of the ovary in some eutherian mammals. Mutations or loss of function of these genes are associated with partial to full sex reversal in mice, humans, and goats.
Monika R. Paranjpe +3 more
wiley +1 more source
Precipitated Toxoid as an Immunizing Agent Against Diphtheria
, 1934 J. N. Baker, D. Gill
openalex +1 more source
NEUTRALIZATION TESTS WITH SERA OF CONVALESCENT OR IMMUNIZED ANIMALS AND THE VIRUSES OF SWINE AND HUMAN INFLUENZA [PDF]
, 1936 Thomas Francis, Richard E. Shope
openalex +1 more source
ESC Heart Failure, EarlyView.In a prospective, randomized study of high‐risk HF patients, simultaneous vaccination against influenza and RSV reduced the risk of the primary composite endpoint (hospitalization for HF, all‐cause death, or infection). The main driver of benefit was a lower incidence of infections.
Jan Biegus +14 more
wiley +1 more source
OBSERVATIONS ON DIPHTHERIA TOXOID AS AN IMMUNIZING AGENT
, 1924 W. H. Park +3 more
openalex +2 more sources
ADJUVANTS IN IMMUNIZATION WITH INFLUENZA VIRUS VACCINES [PDF]
, 1944 William F. Friedewald
openalex +1 more source
ESC Heart Failure, EarlyView.Abstract Aims We have previously shown that patients who develop heart‐reactive antibodies (HRAs) de novo after a heart failure (HF) hospitalization are at increased risk of adverse outcomes, lending weight to the hypothesis that B cells may play a pivotal role in HF progression.
Niklas Beyersdorf +19 more
wiley +1 more source